Hello. Wishing you a Happy New Year.

2024 was a year full of ups and downs. Our company's Anyfusion Cylinder pump, enhanced by incorporating field feedback to improve product quality, has been designated as an innovative medical device by the FDA in numerous hospitals. It has been selected for the STeP program for addressing issues with existing products, such as clinical safety, efficacy, versatility, and cost-effectiveness. Its superiority compared to products from major overseas companies has been confirmed and verified, leading to an increase in usage.

Starting in 2025, we will actively promote domestically and internationally that this is a pharmaceutical infusion pump with long-term reliability and comprehensive real-world clinical references. Leveraging FDA-recognized unique technology, we will establish a foundation to shift the paradigm of pharmaceutical infusion pumps globally, not just domestically, by positioning Anyfusion as the unrivaled clinical competitor for this core medical device. Furthermore, 2025 will be the year we leap forward as a world-leading company with our core technology-based Anyfusion platform items, highly valued in the U.S. industry and stock market. Anyfusion Platform items are breakthrough technology products addressing unmet needs: Cylinder (real-time quantitative, accurate) pump, ACPi Pro, PAMs (prescription-linked automated medication therapy), BT (Hemolysis-Free Transfusion) pump, and MC (Growth and Development for Extremely Preterm Infants) pump. Only Anyfusion technology can deliver these breakthrough products, such as the cylinder pump, which is an FDA Breakthrough Device. This market is projected to be worth hundreds of trillions of won.

Through Anyfusion platform items, we aim for an IPO by 2026, entry into the world's largest market—the U.S.—and globalization. With pure domestic core technology, these unmet needs items align with the U.S. market's emphasis on innovative technology, leadership, respect, and high value assessment. We will pursue Korea's first NASDAQ listing in the bio industry. These products will lead the global medical device market and become blockbuster items.

Just as Korea's pursuit of Japan's industries triggered the “lost 30 years,” emerging industrial nations with imitative catch-up models now threaten not only prices but also technological and quality advantages. They are sweeping away not just foundational industries but even semiconductors and automobiles—the pillars that elevated Korea to advanced nation status—casting a dark shadow over our entire industrial and economic landscape. Japan, possessing leading international competitiveness in foundational fields, overcame its lost 30 years through world-leading materials sector competitiveness and maintains its status as an economic powerhouse.

With an identical catch-up industrial structure, the rapid growth of Chinese manufacturing is making it painfully clear day by day that South Korea, lacking leading-edge technology and burdened by high wages, will plummet into lost industries and economic decline faster and for a longer period than Japan did.

Failing to confront this reality, intoxicated by semiconductor export data that will soon be overtaken, politicians from parties beyond common sense cling only to power, disregarding the nation and its people, ignoring law and citizens, and pursuing self-interest. Their absurd actions damage national dignity and plunge the economy, darkening an already gloomy industrial landscape. Anyfusion will be the technology that shifts the paradigm of pumps. In turbulent times, we will stand out as a rare gem, contributing to the nation's industry and economy, and leap forward as a technology-centric global enterprise.

Since its incorporation in 2001, Maintech Co., Ltd. has anticipated the rise of emerging industrial nations and developed pioneering core source technologies to lead the global market. These technologies have been recognized by the world's top authority, the U.S. FDA, and clinically confirmed and validated. We will swiftly expand the domestic market and pursue globalization.

In Korea, where no company—including major corporations representing our nation in recent times—has achieved success with unique core technologies leading major global markets like Microsoft, Google, Apple, Tesla, or Nvidia, the financial market, academia, and government have undervalued the potential of Anyfusion technology. The lack of coastal awareness and evaluation capabilities compared to the US is evident in the understanding and high appraisal of core technologies by US institutions.

With no precedent of success in global medical device markets using core technology, our perspective and capabilities remain at the level of catch-up products. Pioneering technologies lack comparable benchmarks, leading to undervaluation until they are actually used and understood.

Stakeholders and institutions from advanced nations like the US, Japan, and Europe understood Anyfusion's technology instantly, grasping its potential and value upon explanation. They highly evaluated it, posing questions about the BT pump's possibilities.

The path of a frontier in uncharted territory seems challenging. We will steadfastly strive to become a technology and company that turns adversity into opportunity.

We will become a healthy company.

Thank you.